Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets): recall status

⚠ Recall found. Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets) is named in 1 official recall in our current data. Details and the official notices are below — act on the remedy in the official notice.

Brand: Boehringer Ingelheim Pharmaceuticals

Recalls naming this model

FDA Class II · Drug · July 8, 2026

Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets) recall — Boehringer Ingelheim Pharmaceuticals, Inc.

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.

Official ID D-0657-2026 · Official record ↗

See all Boehringer Ingelheim Pharmaceuticals recalls →

Verify with the official sources:

CPSC — consumer products ↗ (aggregated here)
NHTSA — vehicles, car seats, tires ↗ (aggregated here; use NHTSA's VIN lookup to check a specific vehicle)
FDA — food, drugs, medical devices ↗ (aggregated here)
USDA FSIS — meat, poultry & egg products ↗ (not yet aggregated here)
Recalls.gov — the U.S. government’s all-agency portal ↗

Found something wrong or missing? Report a data error.

Compiled from official public-domain CPSC, NHTSA, and FDA data. Sources last checked July 24, 2026 at 1:09 AM UTC.